CDA | Evidence Driven
CDA | Evidence Driven

Sutent for pancreatic neuroendocrine tumours – Details

Details

Files
Generic Name:
Sunitinib malate
Project Status:
Complete
Therapeutic Area:
Pancreatic Neuroendocrine Tumour
Manufacturer:
Pfizer Canada Inc.
Brand Name:
Sutent
Project Line:
Reimbursement Review
Project Number:
PC0004-000
Performance Metric:
N/A — Predated performance metrics
Strength:
12.5mg, 25mg, 50mg
Tumour Type:
Gastrointestinal
Indications:
Pancreatic neuroendocrine tumours
Funding Request:
Patients with unresectable locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumours, whose disease is progressive
Review Status:
Complete
Sponsor:
Pfizer Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Sunitinib (Sutent) for pNETs - pERC Final Recommendation Final Recommendation May 5, 2012 View PDF
Sunitinib (Sutent) for pNETs - Final Clinical Guidance Report Guidance Reports May 3, 2012 View PDF
Sunitinib (Sutent) for pNETs - Final Economic Guidance Report Guidance Reports May 3, 2012 View PDF
Sunitinib (Sutent) for pNETs - Initial Recommendation Initial Recommendation March 2, 2012 View PDF
Sunitinib (Sutent) for pNETs - PAG Feedback on Initial Recommendation Feedback May 3, 2012 View PDF
Sunitinib (Sutent) for pNETs - Manufacturer (Pfizer Canada Inc.) Feedback on Initial Recommendation Feedback May 3, 2012 View PDF
Sunitinib (Sutent) for pNETs - Patient Advocacy Group (CNETs) COI Declarations Feedback May 3, 2012 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : May 18, 2012